Cluster Headache in United Kingdom
Overview
In the United Kingdom, psychedelics that could help cluster headache patients (including psilocybin, LSD, and DMT) are classified as Class A drugs under the Misuse of Drugs Act 1971 and placed in Schedule 1 of the Misuse of Drugs Regulations 2001, meaning they are considered to have high potential for harm and no recognized medical use. This classification severely restricts access for cluster headache patients, making it impossible to legally obtain these potentially life-changing treatments through medical channels, with no compassionate use exceptions currently available.
The only psychedelic-adjacent substance legally accessible is ketamine (Class B, Schedule 2), which may be prescribed off-label by specialists, primarily through private clinics. There is growing momentum for reform, with cross-party parliamentary support for rescheduling psilocybin to facilitate research and potentially enable medical access, supported by patient advocacy groups like Clusterbusters UK and scientific organizations such as the Centre for Evidence Based Drug Policy and the Beckley Foundation.
FAQ
Legal Status & Framework
Regulatory Landscape
Patient-Specific Information
Advocacy Focus
Open Letter
Help us accelerate access to psychedelic therapies for cluster headache in the UK by signing our open letter.
Take these three steps
Sign the global letter to demand governments and agencies take action now. Anyone anywhere can sign.
After signing the global letter, sign your country's open letter to demand better access to effective treatments for cluster headache in your country.
Become a ClusterFree ambassador by sharing this website and getting involved.
